a drug used with another anticancer drug to treat breast cancer that is her2 positive and has advanced or metastasized (spread to other parts of the body) after treatment with other drugs. lapatinib is also being studied in the treatment of other types of cancer. it is a type of erbb-2 and egfr dual tyrosine kinase inhibitor. also called lapatinib ditosylate, gw572016, and tykerb.
出典:Wikipedia
出典:『Wikipedia』 (2011/08/08 22:59 UTC 版)
Lapatinib (INN), used in the form of lapatinib ditosylate, (USAN) (Tykerb/Tyverb, GSK) is an orally active drug for breast cancer and other solid tumours. It is a dual tyrosine kinase inhibitor which interrupts the HER2 growth receptor pathway. It is used in combination therapy for HER2-positive breast cancer. It has been approved as front-line therapy in triple positive breast cancer and as an adjuvant therapy when patients have progressed on Herceptin.